Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
influenza vaccine H1N1v
- Development stage
- Phase 3
- Lead developer
- GSK
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
**Focetria** is an egg-derived, inactivated, monovalent pandemic influenza vaccine developed by Novartis for prevention of influenza caused by the 2009 pandemic influenza A(H1N1) virus. Each 0.5 mL intramuscular dose contains 7.5 micrograms of influenza-virus surface antigens from an A/California/07/2009(H1N1)-derived strain, formulated with the squalene-based oil-in-water emulsion adjuvant MF59C.1. The viral hemagglutinin and neuraminidase antigens stimulate strain-specific humoral immunity, including hemagglutination-inhibition and neutralizing antibodies; MF59 enhances the magnitude and speed of the immune response. ([ema.europa.eu](https://www.ema.europa.eu/en/medicines/human/EPAR/focetria))
- Brand names
- Focetria
- Other names
- A/California/7/2009 (H1N1)v vaccineinfluenza vaccine H1N1v (surface antigen, inactivated, adjuvanted)MF59-adjuvanted influenza A (H1N1) 2009 monovalent vaccine
02
Targets
HA (Hemagglutinin)N1 NA (Influenza A neuraminidase N1)Neuraminidase
Beyond the preview
Go deeper on influenza vaccine H1N1v.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on influenza vaccine H1N1v.